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ABSTRACT: A peptide-binding assay employing the
HLA class I molecules on intact human B cells is de-
scribed. The peptide antigens are stripped from the HLA
class I molecules by mild acid treatment, after which the
cells are incubated with a FL-labeled reference peptide
together with different concentrations of the peptide of
interest. The effectiveness by which the latter peptide
competes for binding to the HLA class I molecules is
assayed by measuring the amount of HLA-bound FL-
labeled reference peptide with FACscan analysis. The as-
say is easy to perform because there is no need to purify
HLA class I molecules, or to transfect cells with HLA
class I molecules, and no radioactive label is used. More-
ABBREVIATIONS
B-LCL B-lymphoblastoid cell line
BSA bovine serum albumin





HPV human papiiloma virus
over, large panels of HLA-typed human B-cell lines are
available as tools for peptide binding to a vast array of
HLA molecules.
The binding assay was optimized and validated with
peptides of known binding capacity to either HLA-
A»0201 or HLA-A*0301. The kinetics of peptide bind-
ing in this assay were shown to be comparable to that in
assays employing soluble HLA class I molecules. Appli-
cation of the assay in the search for potential HLA-
A*0301 restricted CTL epitopes, derived from HIV-1
polymerase, resulted in the identification of five high-
affinity binding peptides. Human Immunology 44, 189-
198 (1995)
IC50 concentration of peptide needed to inhibit
binding of the FL-labeled peptide to 50%
IMDM ISCOVE's modified Dulbecco's medium
MF mean fluorescence
MHC major histocompatibility complex
PBA196 PBS + BSA \%
PBS phosphate-buffered saline
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INTRODUCTION
Proteins in the cytosoi are processed into peptides and
then transported to the endoplasmic reticuium (ER)
where they bind to major histocompatibility complex
(MHC) class I molecules. The peptide-ciass I complexes
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surface {1], where they are presented to CDS + cytotoxic
T lymphocytes (CTLs) [2-Q.
Several features of MHC class I presentation have now
been elucidated. Allele-specific motifs predictive of pep-
tide binding to MHC class I, based on the presence of
amino acids at anchor positions in the peptide, were
defined by the analysis of naturally processed peptide
pools eluted from class I molecules [reviewed in 5, 6] and
peptide-binding studies [7, 8]. The structures of several
MHC class 1 molecules were studied by x-ray crystallog-
raphy which revealed that these anchor amino acids en-
gage specific pockets in the MHC class I molecule [re-
viewed in 9}. The elucidation of these allele-specific
MHC class I peptide-binding motifs and the definition
of size requirement for peptide binding [10—12] facili-
tate the identification of CTL epitopes in proteins of
interest [13, 14}. The approach is based on scanning the
amino acid sequences of virus-derived proteins or tumor-
specific proteins for the presence of potential class I bind-
ing peptides [15].
Peptide-binding assays employ either cell-bound
MHC class I molecules [16-21] or purified "cell-free"
MHC class I molecules [22—25]. Assays relying on cell-
bound MHC class I molecules are based on upregulation
[17, 18, 21] or reconstitution of MHC class I molecules
[19, 20} as detected by MHC class I conformation-
specific antibodies. Cell-free systems are quantitative and
make use of purified MHC molecules, to which labeled
reference peptides are bound in a competition set-up
[25]. Purification of MHC class I molecules, however, is
laborious and conformational changes may occur during
purification and/or storage.
In the present study we report the utilization of flu-
orescein (FL)-labeled reference peptides that bind to
HLA class! molecules on HLA-homozygous B cell lines,
of which the bourttt peptides have been removed by mild
acid treatment. We show that the binding of FL-labeled
peptides to these peptide-stripped HLA class I molecules
is specific and allows the semiquantitative determination
of the binding capacity of peptides. The kinetics of pep-
tide binding to these peptide-stripped HLA class I mol-
ecules is comparable to that of soluble HLA class I mol-
ecules and independent of biosynthesis of new HLA class
I molecules. We applied this new assay to identify po-
tential HLA-A*0301 restricted conserved CTL epitopes
derived from human immunodeficiency virus (HlV)-l
polymerase.
MATERIAL AND METHODS
Cell lines. The Epstein-Barr Virus-transformed B-lym-
phoblastoid cell lines (B-LCLs) used for the competition
assays are JY (HLA type: A«0201, B7, Cw7, DR4,
DRw6, DPw2) and EKR (HLA type: A3, B7, DR7,
DQw2).
The B-LCLs used to confirm specific binding of ref-
erence peptides are B109, BRM, D100, DUO, K97,
ML, NL, P98, S59, and S99. The HLA type of these cell
lines is given in Fig. 1.
Peptidei. FL-labeled reference peptides were synthesized
as Cys-derivative. Labeling was performed with 4-(io-
doacetamido)fluorescein (Fluka Chemie AG, Buchs,
Switzerland) at pH 7.5 (Na-phospate in water/acetoni-
trile 1:1). The labeled peptides were desalted over Seph-
adex G-10 and further purified by CIS RP-HPLC. La-
beled peptides were characterized by MALDI-MS (Laser-
mat, Finnigan, UK). The reference peptide used for
HLA-A*0301 binding was KVFPC(FL)ALINK (MH^c
= 1521.8, MH^ = 1521.4); the reference peptide
for HLA-A*0201 was FLPSDC(FL)FPSV (MHctlc =
1500.6, MH*TO = 1500.1).
The reference peptides used for binding to HLA-
A*0301 or HLA-A*0201 were published by Sette et al.
[25). In both peptides these investigators introduced a
tyrosine which they used to tag a radioactive label to the
peptide. We have substituted this tyrosine for a cysteine.
The cysteine allowed the conjugation of 4-(iodoaceta-
mido)fluorescein. The polymerase amino acid sequences
of 14 different full-length sequenced HIV-1 virus
strains, LAI, MN, NL43, OY1, SF2, RF, MAL, D31,
CAM1, HAN, ELI, NDK, JRCSF, andJRFL{26], were
screened for possible HLA-A*0301 restricted CTL
epitopes using a scoring system [15]. The HLA-A*0301
motif used was based on the studies of Kubo et al. [8}
and Engelhard [5]. At the anchor at position 2 a L, I, V,
or M was preferred and at the C-terminal anchor a K, R,
or Y was preferred. Peptides were synthesized that con-
tained the mentioned residues at both anchor positions
and were completely conserved among all 14 HIV-1
strains.
Peptides were synthesized by solid-phase strategies on
an automated multiple peptide synthesizer (Abimed
AMS 422, Langenfeld, Germany) using Fmoc-chem-
istry. Peptides were analyzed by reverse-phase HPLC,
dissolved in 20 JJL! dimethyl sulfoxide (DMSO), diluted
in 0.9% NaCl to a peptide concentration of 5 mg/ml,
and stored at — 20°C before usage.
Mild acid treatment of B-LCLs. Mild acid treatment of
HLA-A2 or HLA-A3 on B-LCLs was performed accord-
ing to Bremers modification [manuscript submitted] of
the procedure of Storkus et al. [20]. Briefly, cells were
washed twice with phosphate-buffered saline (PBS) and
then put to rest on ice for 5 minutes. The cells were then
treated 90 seconds with ice-cold citric acid Na2HPO4
buffer (mixture of an equal volume of 0.263 M citric acid
and 0.123 M Na2HPO4) [27]. For HLA-A3 the buffer
was adjusted to pH = 2.9 and to pH = 3.2 for HLA-
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Ul Ĵ O to CJ1 -si
O CJl O <*l O CJ1
tXK (« . BZ .
B109 (U .123.87 .645 .C.6.C.7 Dfla
DUO (U .123. BB .W4 .Cw4.C"7 Dfi3
Jï (A2 - K . CM? DBt




B109 (Al .A23.B? .MS ,D*.O7 ,DR4 .ah6i.Dft-7.OMi
0100 (A11.A24.87 .Bw62.C-7.C-9 ,DR4 .DM .KW.KM)
DUO <AI .W3.S6 .&44 .Cw4.C'7 .DR3 .W! .DQH2 )
599 (A24.U2.B7 .B14 . DhLQ.DFML5.DQM5.DQw6]
S59 (U .U6.B16.B5i .C»l.Cv9 ,D(h.-n.DRwL6.Mtó.OQrf)
K97 (A3 .A32.B7 .514 .07. Dfi7 . .OftiZ.DQiriJ
P98 (A3 A24.B7 .837 .C«A-C*7 ,DRvl3.DRvL5.DO>« )
BRH M .All.335.962 .C«4.C-10.DR4 .DR7 .DQri.OQw?)
H. (A2 Ail.B2T.86a .Cn2.C<«3 ,DR7 .ORU .DOvl.DQwZ)
M. (A2 ,«8.B7 .635 .C>»4.Cw7 ,DRi . D0w5 )
FIGURE 1 Specificity of FL-labeled reference peptides. Reference cell line EKR (HLA-A*0301) was mild acid treated at pH
= 2.9. The reference cell line JY (HLA-A*0201) was mild acid treated at pH = 3.2, and the 10 different other B-LCL lines
were mild acid treated at pH = 2.9, when subjected to incubation with the HLA-A*0301 FL-labeled reference peptide, or at
pH = 3.2 when incubated with the HLA-A*0201 FL-labeled reference peptide. EKR cells are incubated with 150 nM of the
HLA-A*0301 FL-labeied reference peptide (open ban), JY cells are incubated with 150 nM of the HLA-A«0201 FL-labeied
reference peptide (hatched ban), and the 10 different other B-LCL lines were incubated with 150 nM of either the HLA-A*0301
(apen bars) or HLA-A*0201 FL-labeled reference peptide (batched barf), for 4 hours at 26°C. The FI was calculated for each cell
line and the FI of FL-labeled reference peptide bound to EKR (for binding to HLA-A*0301) and the FI of FL-labeled reference
peptide to JY (for binding to HLA-A*020l) was equated to 100% binding. By the formula: (FI cell line/FI reference cell line)
X 10096 the relative peptide-binding percentages of the 10 different B-LCL lines were calculated. The upper left side shows the
full HLA-type of the reference cell lines together with the overlapping HLA-type of other cell lines. The lower left side shows all
10 B-LCL lines with their full HLA-type.
A2; these pH differences are essential for optimal elution
of bound peptides and reconstitution of the MHC class I
molecule with the exogenous added peptide [Bremers,
manuscript submitted]. Immediately thereafter the
eluted cellsjyere buffered with cold ISCOVE's modified
Dulbecco's medium (IMDM), washed with IMDM, and
«suspended at 700.000 cells/ml in IMDM +1.5 Jig/ml
(J2 microglobulin (Sigma, St. Louis, MO, USA).
Peptide competition assay. For competition assays, 25 JJ.1
FL-labeled reference peptide (end concentration: 150 nM
in PBS) was incubated with 25 (il competitor peptide
(different end concentrations in PBS) in a 96-well U-bot-
tom plate (Costar, Cambridge, MA, USA). A total of
100 M-l of the mild acid treated B-LCLs (A2:JY,
A3:EKR) was added to these wells.
The mixture was incubated for 3 or 24 hours at 4°C or
26°C, washed twice with PBS containing 1% bovine
serum albumin (BSA) (PBA1%), «suspended in PBA \%
containing 0.5% paraformaldehyde, and analyzed at a
FACscan (Becton-Dickinson, Etten-Leur, the Nether-
lands).
The mean fluorescence (MF) value obtained in the
experiment without competitor peptide was regarded as
maximal binding and equated to 0% inhibition; the MF
obtained from the experiment without reference peptide
was equated to 100% inhibition.
Percent inhibition of binding was calculated using the
following formula:
{1 — (MF 150 nM reference and competitor peptide
— MF no reference peptide)
-5- (MF 150 nM reference
- MF no reference peptide)] X 100%
In experiments where no competitor peptide was
added the fluorescence index {FI) was calculated to indi-
cate how much fluorescence above the background (no
reference peptide) was measured. The FI = (MF sample
— MF backgroundVMF background.
To block protein synthesis in B-LCLs a final concen-
tration of 100 u,M emetine (Sigma) was used, as shown
previously [27].
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RESULTS
Sensitivity and specificity of FL-labeled reference peptides bind-
ing to HLA clasi I . The reference peptides binding to
HLA-A*0201 and HLA-A*0301 were described and
used in a moiecular binding assay by Sette et al. [25] In
both peptides a tyrosine was used to tag a radioactive
label to the peptide. We substituted this tyrosine with
cysteine, to which 4-(iodoacetamido)fiuorescein was con-
jugated.
The amount of fluorescent peptide needed for the
competition assay was established. For this purpose a
peptide titration was performed. After incubation of 3
hours at 26°C the MF was measured. At concentrations
from 2 nM to 100 nM for the HLA-A*0201 reference
peptide and from 2 nM to 150 nM for the HLA-A*0301
reference peptide a sharp increase in MF was found (data
not shown). Mild acid treatment of the B cells before
incubation wirivFL-labeled reference peptide resulted in
a higher fluorescence maximum and also sharper increase
of the MF at low peptide concentrations (Fig. 2).
In order to investigate if aspecific peptide binding to
cell components, including other HLA class I alleles, at
the surface of the cell line used occurred, 10 different
B-LCL cell lines were incubated with 0 or 150 nM of
FL-labeled reference (either HLA-A*0201 or HLA-
A*0301) peptide. The FI for each cell line was calculated
and the FIs obtained for reference cell lines JY (binding
of peptide to HLA-A*0201) and EKR (binding of pep-
tide to HLA-A*0301) were equated to 100% binding.
To relate the binding of FL-labeled reference peptide to
the 10 different cell lines with the binding of the FL-
labeled reference peptide to JY or EKR, the relative
FIGURE 2 Peptide binding on eluted vs noteluted HLA
class 1 molecules. JY cells (•) and JY cells with HLA class I
molecules mild acid treated (D) were incubated with increas-
ing amounts (nM> of the HLA-A*0201 FL-labeled peptide.
Cells were incubated for 3 hours at 26°C, washed, and MF was
measured at a FACScan. The lines shown are the result of
logarithmic regression analysis of the concentration of FL-
labeled reference peptide versus the MF.
60 120 180 24O 300 360
Time (minutes)
FIGURE 3 Kinetics of peptide binding to mild acid treated
HLA class I molecules. EKR cells were mild acid treated and
incubated with 150 nM of HLA-A*0}01 FL-labeled reference
peptide for different periods of time at 4°C (A), 26°C (D), or
37°C (•). At 10, 20, 40, 90, 180, and 360 minutes the
binding of Fl-labeled peptide was measured. Binding is given
as the fluorescence index (FI). The lines shown for 4°C and
26°C are the result of linear or logarithmic regression analysis,
respectively.
peptide-binding percentages were determined. The rel-
ative peptide-binding percentages of the FL-labeled ref-
erence peptides to each cell line were calculated as: (FI
cell line/ FI reference cell line) X 100%. For both FL-
labeled reference peptides the nonspecific binding to
other cell components, of the cell lines used in the com-
petition assay, never exceeded 20% (Fig. 1). Because the
peptide binding motif of HLA-A*0301 is very similar to
the binding motif of HLA-A11 [8], binding of the HLA-
A*0301 FL-labeled reference peptide to B-LCL cell lines
expressing this allele was also observed (Fig. 1). The cell
line NL binds the HLA-A*0301 FL-labeled reference
peptide. It expresses the HLA-A28 allele of which two
subtypes, HLA-Aw6801 and HLA-Aw6803, shire the
peptide-binding motif with HLA-A*0301 [A. Sette,
personal communication}.
Kinetics if peptide binding to mild acid trtattd HLA class 1
molecules. To study the effect of peptide binding at dif-
ferent temperatures, EKR cells were eluted and incu-
bated with FL-labeled peptide for different periods of
time at 4°C, 26°C, or 37°C. At 4°C the peptide binds
rapidly initially and then increases steadily in time (Fig.
3). Peptide binding at 26°C is faster (Fig. 3). The
amount of peptide bound after 6 hours at 26°C did not
differ from the amount of peptide bound at 4°C. Peptide
binds fast at 37°C but no increase of bound peptide is
found when incubated longer (Fig. 3). The tack of in-
crease in bound peptide at 37°C is probably due to two
HLA Class I Peptide-Binding Assay
phenomena. The HLA class I molecules, present on the
surface of the cell to which no peptide was bound, dis-
integrate at this temperature [21]. Second, the dissoci-
ation of peptides is dramatically faster at 37°C compared
to the dissociation of peptides when incubated at 4°C
{23}.
Binding to mild acid treated class I molecules is not dependent
on de nova protein synthesis. To characterize the interaction
of peptides with cell-associated mild acid treated HLA
molecules, peptide-stripped EKR cells were incubated
with FL-labeled peptide for different periods of time at
4°C or 26°C. As shown in Fig. 4, the fluorescent label-
ing at 4°C of the cells steadily increases in time. The use
of 100 |O.M protein synthesis inhibitor emetine for 1 hour
prior to elution decreased the amount of peptide bound
at 26°C but not at 4°C (Fig. 4).
Thus, the binding of a peptide to mild acid treated
HLA class I molecules at 4°C was unaffected by the use
of a protein-synthesis-inhibiting drug. Because meta-
bolic processes are reduced at 4°C, the binding of pep-
tides to the eluted HLA class I molecules is only depen-
dent on the availability of the HLA class I molecules
already present at the outer surface of the cell.
Competition assay. Plotting MF against the concentration
of FL-labeled reference peptides resulted in a log-shaped
curve. We chose 150 nM of FL-labeled reference peptide
as standard concentration in all competition experi-
ments. The use of 150 nM FL-labeled reference peptide
resulted in a MF of about 4 to 5 times the background
(not shown). The nonlabeled reference peptide was ti-
trated into 150 nM of FL-labeled reference peptide, the
percentage inhibition was calculated and plotted against
10: -
4° C
1 3 4 , 5 1 3
incubation in hours
4.5
FIGURE 4 Binding of FL-labeled pepcide to protein-
synthesis-inhibiting, drug-treated cells. EKR cells were
treated with 10 "4 M emetine (open liars) or not (hatched ban),
for 1 hour prior to mild acid treatment [27]. Then, 150 nM of
HLA-A*0301 FL-labeled reference peptide was added and
binding was monitored at 1, 3, or 4.5 hours of incubation.
Cells were incubated at 26°C or 4°C.
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the concentration of the unlabeled peptide (Fig. 5). In a
24-hour competition assay at 4°C the nonlabeled HLA-
A*0201 or HLA-A*0301 reference peptide needed about
3-5 times (0,4 |U,M and 0,7 flM, respectively) the con-
centration used of the FL-labeled reference peptide to
inhibit binding of the FL-labeled peptide to 50% (IC50)
(Table 1).
To determine the optimal experimental conditions
and to validate the assay we tested peptides derived from
human papilloma virus (HPV)16 E6 and E7 proteins
with known binding properties to HLA-A*0201 or
HLA-A*0301 [28, 29] at different concentrations, for 3
or 24 hours at 4°C or 26°C (Table 1). When the cells
were incubated for 24 hours less peptide was needed
(Table 1). The lowest amount of competitor peptide was
needed when the cells were incubated for 24 hours at 4°C
(Table 1). No difference was observed between an incu-
bation time of 24 hours or 48 hours at 4°C (not shown).
This implicates that the test is more sensitive when equi-
librium is reached. Probably, due to a faster association
of the FL-labeled reference peptide, more competitor
peptide is needed to reach IC50 in short incubations.
Ranking the peptides to their IC,0 shows that when the
cells are incubated at 4°C for 24 hours, their order is
comparable to that found by Kast et al. [28] using the
molecular binding assay (Table 1). All peptides that did
not possess the described binding motif showed low
binding affinity. Taken together these results and the
results of peptide-binding to HLA class I molecules on
emetine-treated cells, we conclude that the competition
assay is best performed at 4°C with an incubation time of
at least 24 hours.
Competition with known CTL epitopes. Five HLA-A*0201-
restricted CTL epitopes, one HLA-A*0301-restricted
CTL epitope, and two HLA-A*0301 peptides, identified
via peptide pool-sequencing, were used to determine the
IC50 values of high affinity binding peptides. The five
peptides tested for binding to HLA-A*0201 all com-
peted very well with an IC,0 *£ 1.7 (J.M (Table 2). The
known HLA-A*0301-restricted CTL epitope derived
from HIV was tested. This peptide, derived from HIV-
nef, bound with an IC50 of 0.5 jJiM. The two peptides,
which were identified via peptide pool sequencing bound
with an IC50 «5 15 (iM (Table 2). We therefore conclude
that peptides competing with an IC50 ̂  15 u.M must be
considered potential CTL epitopes.
Binding of conserved HlV-1 pal sequences to HLA-
A*0301. Twenty peptides 8-11 amino acids long were
selected on the basis of the HLA-A*0301 binding motif
and their conservation in the polymerase gene products
of different HIV-1 strains. The peptides were tested in
the competition assay for 24 hours at 4°C. Nine peptides
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kvfpCfFDalink 150nM flpsdC(FL)fpsv 150nM
10 15 20
competitor peptide
O 5 10 !5 20 25 30 35 « 46 50
competitor peptide //M
FIGURE 5 Competition of nonlabeled reference peptide with FL-labeled reference peptide. EKR cells (left) or JY cells (right)
were incubated with 150 nM of FL-labeled reference peptide, kvfpC(FL)aIink or flpsdC(FL)rpsv, respectively, and increasing
amounts (u,M) of nonlabeled reference peptide. Inhibition of binding was calculated and is shown in relation to the amount of
nonlabeled reference peptide used.
were shown to bind to HLA-A*0301. Four peptides
bind with intermediate affinity and competed with an
IC50 ^15 (xM (Table 3); the other five peptides (marked
with an asterisk) bind with high affinity and competed
with an 1C50 'S 2.9 H-M. Considering the IC50 obtained
with the known CTL epitopes, these five peptides may
be candidate CTL epitopes.
DISCUSSION
In recent years various assays have been developed to
identify potential CTL epitopes in proteins of cellular or
viral origin [16-25, 37^0]. Peptides with a high ca-
pacity to bind to a MHC class ] molecule may be im-
munogenic whereasjpw-affinity binding peptides are not
[29, 41]. We report an assay that employs the HLA class
1 molecules present on human B cells and show that the
kinetics of binding of peptides to these HLA class I
molecules is comparable to the kinetics observed with
soluble HLA class ! molecules [42].
The FL-labeled reference peptides specifically bound
to their HLA molecules and not to other components at
the surface of the cell lines used for the assay (Fig. 1).
The use of a protein synthesis inhibitor decreased the
amount of peptide bound at 26°C but not at 4°C (Fig.
4). This indicates that during incubation at 26°C novel
MHC class 1 molecules reach the cell surface [21], to
which peptides might bind. Due to the limiting amount
of FL-labeled peptide only the competitor peptide will
bind to the de novo produced HLA class I molecules and
therefore a higher amount of competitor peptide is
needed to compete in the assay at 26°C. We conclude
that, because peptides bind at 4°C and emetine has no
effect at this temperature, the binding of peptide to
eluted HLA class 1 molecules occurs at 4°C and is not
determined by metabolic processes.
Luescher et al. [42] reported that binding of peptide
to peptide-loaded HLA molecules at the cell surface did
not take place at 4°C and that binding of peptides was
dependent on de novo produced HLA class I molecules.
However, when these peptide-loaded HLA molecules
were stripped from their peptides by mild acid treatment
the FL-labeled reference peptides did bind at 4°C as
shown in our study (Fig. 3). We observed that the fate
of peptide upon incubation at different temperatures
shows comparable characteristics to those seen with pep-
tide binding to soluble MHC molecules [42]. We there-
fore conclude that the kinetics of peptide binding to
acid-eluted cell-bound MHC molecules are comparable
to those of peptide binding to soluble MHC molecules.
Validation of the assay shows that the assay is most
sensitive when performed at 4°C with an incubation time
of at least 24 hours. The ranking of the HLA-A*0201
and HLA-A*0301 motif-bearing peptides, according to
their 1C,0, is comparable to that seen by Kast et ai. [28].
When the HLA-A*0201 motif-bearing peptides are
ranked to the IC^ reported by Sette et al. [29], ranking
of the motif-bearing peptides is similar in our assay. The
four peptides also tested for binding to HLA-A*0301 in
the cell-free assay, which uses FL-labeled reference pep-
tide [Dnjfhout, manuscript in preparation], competed to
the same extent in the cellular binding assay.
When the competition assay is performed for 3
hours at 4°C, the HPV16 peptides LLMGTLGIV (E7
82-90, HLA-A*0201), KLPQLCTEL (E6 18-26,
HLA-A*0201) which is naturally processed [43], and
HLA Class I Peptide-Binding Assay
TABLE 1 HPV 16 E6 and El peptides tested for binding in competition assay at




























































































































" Amino acid sequence of the HPV peptides.
* Binding capacity (JC50) to the given HLA class I molecule as tested in the molecular binding assay [28]. For some
peptides two IC,0 values are given: HLA-A*Q2Q,, che value at the right of the backslash, was reported in a later publication
[29}; HLA-A*0301, the value at the right side, was determined using a molecular binding assay which employs the same
FL-labded reference pepcide as used in the cellular binding assay [Drijfhouc, manuscript in preparation].
' The presence of the HLA-A*Q201 or HLA-A*Q}01 binding motif in the peptide.
Binding capacity of the peptides is shown as the concentration of peptide needed to inhibit binding of che PL-labeled
peptide EO 50% (IC>0 in u.M).
' The nonlabeled reference peptides; che dash means that their IC)0 in the molecular binding assay is not known.
TABLE 2 Binding capacity of known processed and
presented peptides













































* Amino acid sequence of the peptides.
' Binding capacity (IC,0 in nM) to the given HLA class I molecule as tested
in che molecular binding assay [29}.
' Binding capacity of the peptides in the present study is shown as the con-
cenctacion of pepcide need to inhibit binding of the FL-labeled pepcide to 50SÉ
(IC„ in u-M).
TTLEQQYNK (E6 93-101, HLA-A*0301) are mea-
sured as low-affinity binding peptides. However, these
peptides display a higher affinity in a 24-hour assay.
Obviously, these peptides have a low association rate and
only at equilibrium do they show high-affinity binding.
This means that these peptides must have a low disso-
ciation rate at 4°C. What this observation means, in
terms of eliciting a CTL response by the peptide in vivo,
is still speculative. It could be that the immunologie
importance of a peptide is dependent mainly on the dis-
sociation rate of the peptide.
Two HLA-A*0301-restricted peptides, which were
identified via peptide-pool sequencing, competed with
an IC;0 ^ 15 (J.M. Therefore peptides binding to HLA
class I molecules with an IC50 =S 15 \M are considered
candidate CTL epitopes. All six known CTL epitopes,
however, competed with an IC50 < 2 (J.M. In the search
of potential CTL epitopes it is, therefore, best to focus on
peptides that display binding affinities of approximately
2 (iM.
The screening of HIV polymerase protein sequence for
conserved sequences bearing the HLA-A*0301 motif re-
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TABLE 3 Binding of conserved HIV-1 pol































































- Arnino acid sequence of conserved peptides derived from HIV-1.
* Position of first and last amino acid in HIV-1 polymeraie derived from srrain
JR-CSF.
c Peptides were tested in the competition assay at 4°C with an incubation rime
of 24 hours. The binding capacity of the peptides is shown as the range of the
concentration of peptide needed to inhibit binding of the PL-labeled peptide
to 509Ê {IC50 in (JLM). Peptides marked with a ailtnsk (•) are considered to be
potential CTL epicopes.
suited in the selection of 20 peptides, five of which were
shown to bind with a binding affinity comparable to that
of already known epitopes. These peptides are considered
potential CTL epitopes and their immunogenicity is cur-
rently under investigation.
The system developed has a number of advantages
compared to previously described assays. Native HLA
class I molecules present on the surface of B-LCLs are
used and the binding of peptides is measured via FACS
analysis. The FACscan system is very sensitive and allows
the measurement of low amounts bound FL-labeled pep-
tide (Fig. 2), also in short incubations. The system is
relatively simple because there is no need to purify sol-
uble HLA class I molecules or to transect these molecules
in cells and no radioactive label is used. Although the
data of the assay when it is compared to the molecular
assay is compressed, and therefore discrimination be-
tween high-affinity and very high-affinity binding pep-
tides is more difficult, peptides are categorized in the
same ranking order. Furthermore, in contrast to other
cellular peptide-binding assays, no monoclonal antibod-
ies are needed to detect peptide binding to HLA class I.
Moreover, large panels of HLA-typed B-cell lines are
available for measurement of peptide binding to a vast
array of HLA molecules. Presently the system is also used
successfully for the HLA class 1 molecules HLA-A1 and
HLA-B7
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